

Patrick M Mccarthy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6609364/publications.pdf>

Version: 2024-02-01

11
papers

58
citations

2258059

3
h-index

2053705

5
g-index

11
all docs

11
docs citations

11
times ranked

62
citing authors

#	ARTICLE	IF	CITATIONS
1	Adverse Outcomes With Early Venous Thromboembolism Prophylaxis in Neurosurgical Trauma Patientsâ€”Are We Crossing the Blood-Brain Barrier?. JAMA Surgery, 2022, 157, e215766.	4.3	0
2	Downstaging of Pancreatic Adenocarcinoma With Either Neoadjuvant Chemotherapy or Chemoradiotherapy Improves Survival. Annals of Surgical Oncology, 2022, 29, 6015-6028.	1.5	6
3	AE37: a HER2-targeted vaccine for the prevention of breast cancer recurrence. Expert Opinion on Investigational Drugs, 2021, 30, 5-11.	4.1	19
4	Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer. Clinical Immunology, 2021, 225, 108679.	3.2	19
5	The influence of harvest method on dendritic cell function and clinical outcomes in a randomized trial of a dendritic cell vaccine to prevent recurrences in high-risk melanoma.. Journal of Clinical Oncology, 2021, 39, 9548-9548.	1.6	0
6	Near Complete Pathologic Response to PD-1 Inhibitor and Radiotherapy in a Patient with Locally Advanced Pancreatic Ductal Adenocarcinoma. OncoTargets and Therapy, 2021, Volume 14, 3537-3544.	2.0	7
7	Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma. Melanoma Research, 2021, 31, 378-388.	1.2	3
8	542â€”Randomized trial of tumor lysate particle only vaccine vs. tumor lysate particle-loaded, dendritic cell vaccine to prevent recurrence of resected stage III/IV melanoma: 36-month analysis. , 2021, 9, A571-A571.		0
9	300â€”Final analysis of a prospective, randomized, double-blind, placebo-controlled phase IIb trial of tumor lysate, particle-loaded, dendritic cell vaccine in stage III/IV melanoma: 36-month analysis. , 2020, 8, A327-A327.		2
10	431â€”Prospective, randomized trial of the tumor lysate, particle only vaccine compared to the tumor lysate, particle-loaded, dendritic cell vaccine to prevent recurrence for resected stage III/IV melanoma. , 2020, , .		1
11	310â€”The effect of pretreatment with G-CSF prior to dendritic cell collection during the phase IIb trial of an autologous DC-based vaccine for advanced, resectable melanoma. , 2020, , .		1